Literature DB >> 34870639

The COVID-19 Healthcare Personnel Study (CHPS): Overview, Methods, and Preliminary Findings.

Charles DiMaggio1, David Abramson2, Ezra S Susser3, Christina W Hoven4, Qixuan Chen5, Howard F Andrews6, Daniel Herman7, Jonah Kreniske8, Megan Ryan9, Ida Susser10, Lorna E Thorpe11, Guohua Li12.   

Abstract

INTRODUCTION: The COVID-19 Healthcare Personnel Study (CHPS) was designed to assess adverse short-term and long-term physical and mental health impacts of the coronavirus disease-2019 (COVID-19) pandemic on New York's physicians, nurse practitioners, and physician assistants.
METHODS: Online population-based survey. Survey-weighted descriptive results, frequencies, proportions, and means, with 95% confidence intervals (95% CI). Odds ratios (ORs) for association.
RESULTS: Over half (51.5%; 95% CI: 49.1, 54.0) of respondents worked directly with COVID-19 patients; 27.3% (95% CI: 22.5, 32.2) tested positive. The majority (57.6%; 95% CI: 55.2, 60.0) reported a negative impact on their mental health. Negative mental health was associated with COVID-19 symptoms (OR=1.7, 95% CI: 1.3, 2.1) and redeployment to unfamiliar functions (OR=1.3, 95% CI: 1.1, 1.6).
CONCLUSIONS: A majority of New York health care providers treated COVID-19 patients and reported a negative impact on their mental health.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 34870639     DOI: 10.1097/ANA.0000000000000813

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  1 in total

1.  Occupational Conditions Associated With Negative Mental Health Outcomes in New York State Health Professionals During the COVID-19 Pandemic.

Authors:  Keely Cheslack-Postava; Michaeline Bresnahan; Megan Ryan; George J Musa; Lawrence Amsel; Charles DiMaggio; Howard F Andrews; Ezra Susser; Guohua Li; David M Abramson; Barbara H Lang; Christina W Hoven
Journal:  J Occup Environ Med       Date:  2022-06-16       Impact factor: 2.306

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.